Free Access
Med Sci (Paris)
Volume 26, Number 3, Mars 2010
Page(s) 267 - 272
Section M/S revues
Published online 15 March 2010
  1. Lejeune J, Gautier M, Turpin R. Study of somatic chromosomes from 9 mongoloid children. CR Hebd Seances Acad Sci 1959; 248 : 1721–2. [Google Scholar]
  2. Hassold T, Hunt P. To err (meiotically) is human: the genesis of human aneuploidy. Nat Rev Genet 2001; 2 : 280–91. [Google Scholar]
  3. Antonarakis SE. Parental origin of the extra chromosome in trisomy 21 as indicated by analysis of DNA polymorphisms. Down syndrome collaborative group. N Engl J Med 1991; 324 : 872–6. [Google Scholar]
  4. Savage AR, Petersen MB, Pettay D, et al. Elucidating the mechanisms of paternal non-disjunction of chromosome 21 in humans. Hum Mol Genet 1998; 7 : 1221–7. [Google Scholar]
  5. Lamb NE, Feingold E, Savage A, et al. Characterization of susceptible chiasma configurations that increase the risk for maternal nondisjunction of chromosome 21. Hum Mol Genet 1997; 6 : 1391–9. [Google Scholar]
  6. Warren AC, Chakravarti A, Wong C, et al. Evidence for reduced recombination on the nondisjoined chromosomes 21 in Down syndrome. Science 1987; 237 : 652–4. [Google Scholar]
  7. Lamb NE, Freeman SB, Savage-Austin A, et al. Susceptible chiasmate configurations of chromosome 21 predispose to non-disjunction in both maternal meiosis I and meiosis II. Nat Genet 1996; 14 : 400–5. [Google Scholar]
  8. Antonarakis SE, Avramopoulos D, Blouin JL, Talbot CC Jr, Schinzel AA. Mitotic errors in somatic cells cause trisomy 21 in about 4.5% of cases and are not associated with advanced maternal age. Nat Genet 1993; 3 : 146–50. [Google Scholar]
  9. Warburton D. Biological aging and the etiology of aneuploidy. Cytogenet Genome Res 2005; 111 : 266–72. [Google Scholar]
  10. Pellestor F, Anahory T, Hamamah S. Effect of maternal age on the frequency of cytogenetic abnormalities in human oocytes. Cytogenet Genome Res 2005; 111 : 206–12. [Google Scholar]
  11. Allen EG, Freeman SB, Druschel C, et al. Maternal age and risk for trisomy 21 assessed by the origin of chromosome nondisjunction: a report from the Atlanta and National Down Syndrome Projects. Hum Genet 2009; 125 : 41–52. [Google Scholar]
  12. Oliver TR, Feingold E, Yu K, et al. New insights into human nondisjunction of chromosome 21 in oocytes. PLoS Genet 2008; 4 : e1000033. [Google Scholar]
  13. Hodges RJ, Wallace EM. Testing for Down syndrome in the older woman: a risky business ? Aust NZ J Obstet Gynaecol 2005; 45 : 486–8. [Google Scholar]
  14. Epstein CJ, Korenberg JR, Anneren G, et al. Protocols to establish genotype-phenotype correlations in Down syndrome. Am J Hum Genet 1991; 49 : 207–35. [Google Scholar]
  15. Gardiner K, Fortna A, Bechtel L, Davisson MT. Mouse models of Down syndrome: how useful can they be ? Comparison of the gene content of human chromosome 21 with orthologous mouse genomic regions. Gene 2003; 318 : 137–47. [Google Scholar]
  16. Davisson MT, Schmidt C, Akeson EC. Segmental trisomy of murine chromosome 16: a new model system for studying Down syndrome. Prog Clin Biol Res 1990; 360 : 263–80. [Google Scholar]
  17. Sago H, Carlson EJ, Smith DJ, et al. Ts1Cje, a partial trisomy 16 mouse model for Down syndrome, exhibits learning and behavioral abnormalities. Proc Natl Acad Sci USA 1998; 95 : 6256–61. [Google Scholar]
  18. Shinohara T, Tomizuka K, Miyabara S, et al. Mice containing a human chromosome 21 model behavioral impairment and cardiac anomalies of Down’s syndrome. Hum Mol Genet 2001; 10 : 1163–75. [Google Scholar]
  19. Tan YH, Tischfield J, Ruddle FH. The linkage of genes for the human interferon-induced antiviral protein and indophenol oxidase-B traits to chromosome G-21. J Exp Med 1973; 137 : 317–30. [Google Scholar]
  20. Hattori M, Fujiyama A, Taylor TD, et al. The DNA sequence of human chromosome 21. Nature 2000; 405 : 311–9. [Google Scholar]
  21. Gardiner K, Costa AC. The proteins of human chromosome 21. Am J Med Genet C Semin Med Genet 2006; 142C : 196–205. [Google Scholar]
  22. Dermitzakis ET, Reymond A, Lyle R, et al. Numerous potentially functional but non-genic conserved sequences on human chromosome 21. Nature 2002; 420 : 578–82. [Google Scholar]
  23. Kuhn DE, Nuovo GJ, Martin MM, et al. Human chromosome 21-derived miRNAs are overexpressed in down syndrome brains and hearts. Biochem Biophys Res Commun 2008; 370 : 473–7. [Google Scholar]
  24. Reymond A, Marigo V, Yaylaoglu MB, et al. Human chromosome 21 gene expression atlas in the mouse. Nature 2002; 420 : 582–6. [Google Scholar]
  25. Antonarakis SE, Lyle R, Dermitzakis ET, Reymond A, Deutsch S. Chromosome 21 and down syndrome: from genomics to pathophysiology. Nat Rev Genet 2004; 5 : 725–38. [Google Scholar]
  26. Rachidi M, Lopes C. Mental retardation and associated neurological dysfunctions in Down syndrome: a consequence of dysregulation in critical chromosome 21 genes and associated molecular pathways. Eur J Paediatr Neurol 2008; 12 : 168–82. [Google Scholar]
  27. Ait Yahya-Graison E, Aubert J, Dauphinot L, et al. Classification of human chromosome 21 gene-expression variations in Down syndrome: impact on disease phenotypes. Am J Hum Genet 2007; 81 : 475–91. [Google Scholar]
  28. Prandini P, Deutsch S, Lyle R, et al. Natural gene-expression variation in Down syndrome modulates the outcome of gene-dosage imbalance. Am J Hum Genet 2007; 81 : 252–63. [Google Scholar]
  29. FitzPatrick DR. Transcriptional consequences of autosomal trisomy: primary gene dosage with complex downstream effects. Trends Genet 2005; 21 : 249–53. [Google Scholar]
  30. Mao R, Zielke CL, Zielke HR, Pevsner J. Global up-regulation of chromosome 21 gene expression in the developing Down syndrome brain. Genomics 2003; 81 : 457–67. [Google Scholar]
  31. Delabar JM, Theophile D, Rahmani Z, et al. Molecular mapping of twenty-four features of Down syndrome on chromosome 21. Eur J Hum Genet 1993; 1 : 114–24. [Google Scholar]
  32. Korenberg JR. Molecular mapping of the Down syndrome phenotype. Prog Clin Biol Res 1990; 360 : 105–15. [Google Scholar]
  33. Rahmani Z, Blouin JL, Creau-Goldberg N, et al. Down syndrome critical region around D21S55 on proximal 21q22.3. Am J Med Genet 1990; 7 (suppl) : 98–103. [Google Scholar]
  34. Ronan A, Fagan K, Christie L, et al. Familial 4.3 Mb duplication of 21q22 sheds new light on the Down syndrome critical region. J Med Genet 2007; 44 : 448–51. [Google Scholar]
  35. Korenberg JR, Chen XN, Schipper R, et al. Down syndrome phenotypes: the consequences of chromosomal imbalance. Proc Natl Acad Sci USA 1994; 91 : 4997–5001. [Google Scholar]
  36. Shapiro BL. The Down syndrome critical region. J Neural Transm 1999; 57 (suppl) : 41–60. [Google Scholar]
  37. Olson LE, Richtsmeier JT, Leszl J, Reeves RH. A chromosome 21 critical region does not cause specific Down syndrome phenotypes. Science 2004; 306 : 687–90. [Google Scholar]
  38. Olson LE, Roper RJ, Sengstaken CL, et al. Trisomy for the Down syndrome “critical region“ is necessary but not sufficient for brain phenotypes of trisomic mice. Hum Mol Genet 2007; 16 : 774–82. [Google Scholar]
  39. Lyle R, Gehrig C, Neergaard-Henrichsen C, Deutsch S, Antonarakis SE: Gene expression from the aneuploid chromosome in a trisomy mouse model of down syndrome. Genome Res 2004; 14 : 1268–74. [Google Scholar]
  40. Korbel JO, Tirosh-Wagner T, Urban AE, et al. The genetic architecture of Down syndrome phenotypes revealed by high-resolution analysis of human segmental trisomies. Proc Natl Acad Sci USA 2009; 106 : 12031–6. [Google Scholar]
  41. Reeves RH, Baxter LL, Richtsmeier JT. Too much of a good thing: mechanisms of gene action in Down syndrome. Trends Genet 2001; 17 : 83–8. [Google Scholar]
  42. Crispino JD. GATA1 mutations in Down syndrome: implications for biology and diagnosis of children with transient myeloproliferative disorder and acute megakaryoblastic leukemia. Pediatr Blood Cancer 2005; 44 : 40–4. [Google Scholar]
  43. Hasle H. Pattern of malignant disorders in individuals with Down’s syndrome. Lancet Oncol 2001; 2 : 429–36. [Google Scholar]
  44. Guidi S, Bonasoni P, Ceccarelli C, et al. Neurogenesis impairment and increased cell death reduce total neuron number in the hippocampal region of fetuses with Down syndrome. Brain Pathol 2008; 18 : 180–97. [Google Scholar]
  45. Lorenzi HA, Reeves RH. Hippocampal hypocellularity in the Ts65Dn mouse originates early in development. Brain Res 2006; 1104 : 153–9. [Google Scholar]
  46. Arron JR, Winslow MM, Polleri A, et al. NFAT dysregulation by increased dosage of DSCR1 and DYRK1A on chromosome 21. Nature 2006; 441 : 595–600. [Google Scholar]
  47. Canzonetta C, Mulligan C, Deutsch S, et al. DYRK1A-dosage imbalance perturbs NRSF/REST levels, deregulating pluripotency and embryonic stem cell fate in Down syndrome. Am J Hum Genet 2008; 83 : 388–400. [Google Scholar]
  48. Fernandez F, Morishita W, Zuniga E, et al. Pharmacotherapy for cognitive impairment in a mouse model of Down syndrome. Nat Neurosci 2007; 10 : 411–3. [Google Scholar]
  49. Costa AC, Scott-McKean JJ, Stasko MR. Acute injections of the NMDA receptor antagonist memantine rescue performance deficits of the Ts65Dn mouse model of Down syndrome on a fear conditioning test. Neuropsychopharmacology 2008; 33 : 1624–32. [Google Scholar]
  50. Guedj F, Sebrie C, Rivals I, et al. Green tea polyphenols rescue of brain defects induced by overexpression of DYRK1A. PLoS One 2009; 4 : e4606. [Google Scholar]
  51. Turleau C, Vekemans M. Nouvelles données en génétique chromosomique. Med Sci (Paris) 2005; 21 : 940–6. [Google Scholar]
  52. Terret ME, Wassmann K. Le point faible méiotique : la première division. Med Sci (Paris) 2008; 24 : 197–203. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.